S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Wall Street Gains as Iran Conflict Fears Recede

President Donald Trump’s pledge to avoid military strikes against Iran ahead of the mid-term elections provided a reprieve for investors, triggering a broad market rally. The Dow Jones Industrial Average added 423.31 points, while the S&P 500 climbed toward record territory as geopolitical anxiety cooled across major asset classes.

Wall Street Gains as Iran Conflict Fears Recede

The Dow finished at 51,654.95, a 0.83% increase, while the S&P 500 rose 0.59% to 7,811.54. The Nasdaq Composite gained 0.64% to 27,366.17. Despite the optimism in equities, energy markets remained turbulent; oil futures rose 0.4% to $91.85 a barrel as traders braced for Hurricane Isaias. BP responded by evacuating its Na Kika and Thunder Horse platforms in the Gulf of Mexico. Meanwhile, diesel futures softened following news that Russia would supply fuel to address domestic shortages for farmers and truckers.

Treasury markets showed mixed results, with the 10-year note yield nudging to 5.243%, hovering near multi-decade highs. Corporate shifts also drove volatility: T-Mobile, AT&T, and Verizon shares slumped between 8.7% and 13% after SpaceX announced an $8 billion purchase of wireless spectrum. Conversely, Humana surged 12% to $431.87 following positive updates on its Medicare Advantage plan ratings. These developments arrive against a backdrop of cooling consumer sentiment, with the University of Michigan’s index slipping to 46.3 in October.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!